For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson & Johnson CEO Joaquin Duato said.

The most substantial impact comes from tariffs against China and retaliatory tariffs from China. Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.

Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

The costs will be felt primarily within the company’s medical technology unit, which makes a range of medical devices and surgical products.

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Healthcare and medical technology company Johnson & Johnson (JNJ) has reported first-quarter financial results that beat Wall Street ...

Stocks opened higher Tuesday, with tech and bank names leading the charge as investors welcomed a morning packed with strong earnings and fresh deal buzz. Big banks were in rally mode: Citigroup, Bank ...

The New Brunswick, N.J.-based company raised its full-year sales guidance to a range of $91 billion to $91.8 billion, from its prior outlook of $89.2 billion to $90 billion. It said its outlook ...

U.S. stock futures were little changed Tuesday after two back-to-back days of gains on cautious tariff optimism.

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war ...